摘要
目的探析糖尿病肾病患者接受百令胶囊联合厄贝沙坦治疗的临床疗效。方法该科室将2016年1月—2021年4月该院接诊的52例糖尿病肾病患者随机分成两组,26例接受厄贝沙坦治疗患者为对照组,26例接受百令胶囊联合厄贝沙坦治疗患者为观察组,关注血糖水平、临床疗效及不良反应。结果观察组经治疗,患者空腹血糖(6.64±1.11)mmol/L、餐后2 h血糖(7.48±1.04)mmol/L,血糖水平虽有所下降,但与对照组相比差异无统计学意义(P>0.05);与对照组相比,观察组经诊治,患者血尿素氮(BUN)(18.35±3.76)mmol/L、血肌酐(Scr)(852.32±9.13)μmol/L、尿酸(UA)(487.52±10.37)μmol/L、血β2-微球蛋白(β2-MG)(21.34±2.89)mmol/L更优,差异有统计学意义(P<0.05)。观察组与对照组疗效总有效率为96.15%与69.23%,两者差异有统计学意义(χ^(2)=4.837,P<0.05)。观察组与对照组不良反应发生率为19.23%与46.15%,两组差异有统计学意义(χ^(2)=4.282,P<0.05)。结论糖尿病肾病患者接受百令胶囊与厄贝沙坦联合治疗,血糖、肾功能改善效果好,临床疗效优于厄贝沙坦单独治疗。
Objective To explore the clinical efficacy of Bailing capsule combined with irbesartan in patients with diabetic nephropathy.Methods The department randomly divided 52 patients with diabetic nephropathy admitted to the hospital from January 2016 to April 2021 into two groups,26 patients receiving irbesartan treatment as the control group,and 26 patients receiving Bailing capsule combined with Irbesartan were in the observation group,paying attention to blood glucose levels,clinical efficacy and adverse reactions.Results After treatment,the patients in the observation group showed fasting blood glucose(6.64±1.11)mmol/L and 2 h postprandial blood glucose(7.48±1.04)mmol/L.Although the blood glucose level decreased,there was no statistically difference compared with the control group(P>0.05).Compared with the control group,the observation group was diagnosed and treated with BUN(18.35±3.76)mmol/L,Scr(852.32±9.13)μmol/L,UA(487.52±10.37)μmol/L,β2-MG(21.34±2.89)mmol/L being better,and the difference was statistically significant(P<0.05).The total effective rates of the observation group and the control group were 96.15%and 69.23%,the difference was statistically significant(χ^(2)=4.837,P<0.05).The incidence of adverse reactions between the observation group and the control group was 19.23%and 46.15%.The difference between the two groups was statistically significant(χ^(2)=4.282,P<0.05).Conclusion In patients with diabetic nephropathy who receive the combined treatment of Bailing Capsule and Irbesartan,the blood glucose and renal function are improved,and the clinical effect is better than that of Irbesartan alone.
作者
程娟
CHENG Juan(Department of Nephrology,People's Hospital of Liuhe District,Nanjing,Jiangsu Province,211500 China)
出处
《糖尿病新世界》
2021年第13期190-193,共4页
Diabetes New World Magazine
关键词
糖尿病肾病
百令胶囊
厄贝沙坦
临床疗效
Diabetic nephropathy
Bailing capsule
Irbesartan
Clinical efficacy
